{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:15:56Z","timestamp":1788322556754,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cancer of unknown primary (CUP) is a malignant and aggressive tumor whose primary origin is still unknown despite thorough evaluation. CUP can be life-threatening with a median overall survival of less than 1 year based on empirical chemotherapy. Gene detection technology advances the driver gene detection of malignant tumors and the appropriate precise therapy. Immunotherapy has ushered in a new era in cancer therapy, changing the way advanced tumors, including CUP, are treated. Combined with comprehensive clinical and pathological investigations, molecular analysis of the original tissue and detection of potential driver mutations may provide therapeutic recommendations for CUP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 52-year-old female was admitted to hospital for dull abdominal pain, with peripancreatic lesions below the caudate lobe of the liver and posterior peritoneal lymph nodes enlargement. Conventional biopsy under endoscopic ultrasonography and laparoscopic biopsy both revealed poorly differentiated adenocarcinoma based on immunohistochemical series. To help identify tumor origin and molecular characteristics, 90-gene expression assay, tumor gene expression profiling with Next-generation sequencing (NGS) method and Immunohistochemical expression of PD-L1 were employed. Although no gastroesophageal lesions discovered by gastroenteroscopy, the 90-gene expression assay yielded a similarity score and prompted the most likely primary site was gastric\/esophagus cancer. NGS revealed high TMB (19.3mutations\/Mb) but no druggable driver genes identified. The Dako PD-L1 22C3 assay IHC assay for PD-L1 expression revealed a tumor proportion score (TPS) of 35%. Given the presence of negative predictive biomarkers for immunotherapy, including adenomatous polyposis coli (APC) c.646C&amp;gt;T mutation at exon 7 and Janus kinase 1(JAK1), the patient received immunochemotherapy instead of immunotherapy alone. She was successfully treated with nivolumab plus carboplatin and albumin-bound nanoparticle paclitaxel for six cycles and nivolumab maintenance, which achieved a complete response (CR) maintained for 2 years without severe adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This case highlights the value of multidisciplinary diagnosis and individual precision treatment in CUP. Further investigation is needed as an individualized treatment approach combining immunotherapy and chemotherapy based on tumor molecular characteristics and immunotherapy predictors is expected to improve the outcome of CUP therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1181444","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:33:23Z","timestamp":1681878803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature"],"prefix":"10.3389","volume":"14","author":[{"given":"Jin","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"m4050","DOI":"10.1136\/bmj.m4050","article-title":"Cancer of unknown primary","volume":"371","author":"Lee","year":"2020","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"23074","DOI":"10.1038\/s41598-021-02543-1","article-title":"Real-world data analysis of patients with cancer of unknown primary","volume":"11","author":"Kang","year":"2021","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903544592","article-title":"Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study","volume":"49","author":"M\u00f8ller","year":"2010","journal-title":"Acta Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0112","article-title":"Paclitaxel\/carboplatin plus bevacizumab\/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site","volume":"14","author":"Hainsworth","year":"2009","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21416","article-title":"Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie pearl cancer research network phase II trial","volume":"104","author":"Hainsworth","year":"2005","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03512-4","article-title":"AI-Based pathology predicts origins for cancers of unknown primary","volume":"594","author":"Lu","year":"2021","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"PO.18.00002","DOI":"10.1200\/PO.18.00002","article-title":"Mutational signature and transcriptomic classification analyses as the decisive diagnostic tools for a cancer of unknown primary","volume":"2","author":"Bagge","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2020.06.005","article-title":"Development and clinical validation of a 90-gene expression assay for identifying tumor tissue origin","volume":"22","author":"Ye","year":"2020","journal-title":"J Mol Diagn"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.11.002","article-title":"Cancer of unknown primary in the molecular era","volume":"7","author":"Kato","year":"2021","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100407","DOI":"10.1016\/j.esmoop.2022.100407","article-title":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","volume":"7","author":"Ding","year":"2022","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13293","article-title":"Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown","author":"Kato","year":"2022","journal-title":"Mol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13597","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design","volume":"26","author":"Ross","year":"2021","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000347corr1","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2020.10.024","article-title":"Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: case report","volume":"60","author":"Kamada","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20220128-00068","article-title":"[New strategies for the treatment of carcinoma of unknown primary]","volume":"45","author":"Li","year":"2023","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1181444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:33:47Z","timestamp":1681878827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1181444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2023.1181444"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1181444","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"article-number":"1181444"}}